ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Nebraska » Hematology Oncology

Top Hematology Oncology Prescribers in Nebraska

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
VINCENT BJORLING M.D.

Hematology Oncology

5,553

$581K

370
327 are 65+

8%
patients receiving schedule two controlled substances

Avg: 7%

11%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 16%

$105
Average prescription price

Avg: $380

DAVID JOHNSON MD

Hematology Oncology

2,245

$966K

401
353 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

10%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 16%

$430
Average prescription price

Avg: $380

WALLACE PETERSON MD

Hematology Oncology

1,853

$689K

221
186 are 65+

16%
patients receiving schedule two controlled substances

Avg: 7%

11%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 16%

$372
Average prescription price

Avg: $380

SUSAN KAMBHU M.D.

Hematology Oncology

1,640

$340K

310
239 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

12%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 16%

$207
Average prescription price

Avg: $380

NATHAN GREEN DO

Hematology Oncology

1,407

$291K

190
162 are 65+

7%
patients receiving schedule two controlled substances

Avg: 7%

7%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 16%

$207
Average prescription price

Avg: $380

GEORGE BASCOM M.D.

Hematology Oncology

1,311

$911K

175
161 are 65+

13%
patients receiving schedule two controlled substances

Avg: 7%

8%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 16%

$695
Average prescription price

Avg: $380

ALAN BERG MD

Hematology Oncology

1,289

$506K

182
168 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

9%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$392
Average prescription price

Avg: $380

PETER SILBERSTEIN M.D.

Hematology Oncology

1,162

$518K

109
72 are 65+

20%
patients receiving schedule two controlled substances

Avg: 7%

19%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$446
Average prescription price

Avg: $380

MARIA EDITHA DELA FUENTE-DE VILLA M.D.

Hematology Oncology

1,118

$298K

169
151 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$267
Average prescription price

Avg: $380

RYAN RAMAEKERS MD

Hematology Oncology

1,055

$315K

137
127 are 65+

12%
patients receiving schedule two controlled substances

Avg: 7%

11%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$299
Average prescription price

Avg: $380

IRINA POPA MD

Hematology Oncology

1,041

$215K

141
124 are 65+

0%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 16%

$207
Average prescription price

Avg: $380

STEFANO TARANTOLO M.D.

Hematology Oncology

1,034

$1.12M

159
144 are 65+

9%
patients receiving schedule two controlled substances

Avg: 7%

15%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 16%

$1088
Average prescription price

Avg: $380

NICK HARTL M.D.

Hematology Oncology

988

$345K

105
95 are 65+

0%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$349
Average prescription price

Avg: $380

STEPHEN LEMON MD

Hematology Oncology

973

$229K

134
121 are 65+

9%
patients receiving schedule two controlled substances

Avg: 7%

11%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 16%

$235
Average prescription price

Avg: $380

JAMES COMMERS M.D.

Hematology Oncology

973

$582K

181
156 are 65+

9%
patients receiving schedule two controlled substances

Avg: 7%

10%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 16%

$598
Average prescription price

Avg: $380

STACEY KNOX M.D.

Hematology Oncology

952

$208K

149
126 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

9%
prescriptions for brand name drugs

Avg: 16%

$218
Average prescription price

Avg: $380

MARK HUTCHINS MD

Hematology Oncology

941

$628K

150
137 are 65+

10%
patients receiving schedule two controlled substances

Avg: 7%

13%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 16%

$668
Average prescription price

Avg: $380

JEAN GREM MD

Hematology Oncology

899

$92.3K

95
73 are 65+

26%
patients receiving schedule two controlled substances

Avg: 7%

16%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 16%

$103
Average prescription price

Avg: $380

MARGARET BLOCK M.D.

Hematology Oncology

898

$183K

168
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$204
Average prescription price

Avg: $380

ROBERT LANGDON M.D.

Hematology Oncology

882

$402K

176
161 are 65+

9%
patients receiving schedule two controlled substances

Avg: 7%

15%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$456
Average prescription price

Avg: $380

MEHMET COPUR MD

Hematology Oncology

835

$442K

160
139 are 65+

9%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$529
Average prescription price

Avg: $380

JONI TILFORD MD

Hematology Oncology

819

$313K

134
115 are 65+

8%
patients receiving schedule two controlled substances

Avg: 7%

10%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 16%

$382
Average prescription price

Avg: $380

RABIH FAHED M.D.

Hematology Oncology

788

$97.2K

142
122 are 65+

0%
patients receiving schedule two controlled substances

Avg: 7%

13%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

6%
prescriptions for brand name drugs

Avg: 16%

$123
Average prescription price

Avg: $380

CYNTHIA LEWIS MD

Hematology Oncology

783

$541K

107
96 are 65+

0%
patients receiving schedule two controlled substances

Avg: 7%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 16%

$691
Average prescription price

Avg: $380

RALPH HAUKE MD

Hematology Oncology

755

$288K

136
124 are 65+

17%
patients receiving schedule two controlled substances

Avg: 7%

15%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 16%

$382
Average prescription price

Avg: $380

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank